Versant-backed Stablix has launched to use heterobifunctional moecules to tap into the ubiquitin-proteasome system--but they're not crunching down proteins, they're trying to restore their function. My story: cen.acs.org/pharmaceutical…

We are excited to announce our Series A launch to pioneer this new therapeutic white space and address a number of devastating diseases! #targetedproteinstabilization #stablix #TPS businesswire.com/news/home/2021…

Exciting start to the week. We are thrilled to welcome Tony Kingsley!

Our COO and co-founder, Kevin Sprott, is thrilled to speak in a panel discussion at the #wellsfargo 2023 Targeted Protein Degradation (#TPD) Virtual Summit tomorrow (2p EST), as we establish a new paradigm for restoring protein function. tinyurl.com/5328duvj

We’re thrilled to announce our collaboration with Vertex Pharmaceuticals to discover & develop #TPS (targeted protein stabilization) therapeutics. Learn how we’re exploring the potential of targeted protein #deubiquitination for patients in need of breakthroughs: stablix.com/stablixandvert…

Why is our collaboration with Vertex Pharmaceuticals the perfect match? Our CEO, Tony Kingsley, explains: “We bring DUB biology and chemistry, they bring the target disease and disease expertise.” Check out the full article by Nicole DeFeudis of Endpoints News here! 👇 endpts.com/vertex-buys-in…

How are we #TakingBOLDAction to pioneer targeted protein #deubiquitination therapeutics? Tomorrow, Chief Scientific Officer Eddine Saiah will share how we're aiming to redefine #druggability during WuXi AppTec’s “BOLD: Innovation That Matters." Register: wxpress.wuxiapptec.com/detail/898/BOL…

Check out the WuXi AppTec “BOLD: Innovation That Matters” event happening today. Hear from our CSO Eddine Saiah on how we’re expanding the definition of druggability by unlocking the power of targeted protein #deubiquination. Tune in: wxpress.wuxiapptec.com/detail/898/BOL… #TakingBOLDAction